C12N 2740/13043
Viral genome or elements thereof as genetic vector
Official title: viral genome or elements thereof as genetic vector
C12N2740/13043 (Viral genome or elements thereof as genetic vector) appears on 538 US grants and 635 published applications in this corpus.
Search patents in C12N- Granted patents
- 538
- Published applications
- 635
- Assignees
- 397
- Inventors
- 1,463
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 2 | 0 |
| 1991 | 1 | 0 |
| 1992 | 3 | 0 |
| 1993 | 5 | 0 |
| 1994 | 4 | 0 |
| 1995 | 8 | 0 |
| 1996 | 11 | 0 |
| 1997 | 33 | 0 |
| 1998 | 27 | 0 |
| 1999 | 37 | 0 |
| 2000 | 30 | 0 |
| 2001 | 38 | 8 |
| 2002 | 30 | 56 |
| 2003 | 22 | 41 |
| 2004 | 29 | 41 |
| 2005 | 14 | 37 |
| 2006 | 18 | 35 |
| 2007 | 12 | 22 |
| 2008 | 15 | 33 |
| 2009 | 15 | 17 |
| 2010 | 17 | 17 |
| 2011 | 6 | 15 |
| 2012 | 10 | 20 |
| 2013 | 6 | 9 |
| 2014 | 21 | 14 |
| 2015 | 9 | 5 |
| 2016 | 6 | 13 |
| 2017 | 5 | 10 |
| 2018 | 7 | 16 |
| 2019 | 11 | 16 |
| 2020 | 6 | 15 |
| 2021 | 11 | 31 |
| 2022 | 10 | 46 |
| 2023 | 13 | 28 |
| 2024 | 16 | 32 |
| 2025 | 15 | 34 |
| 2026 | 13 | 24 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Chimeric antigen receptors with CD20 safety switch22 Sep 2026US 12,742,001 B2St. Jude Children?S Research Hospital
- Damage-targeted treatments of disease16 Jun 2026US 12,653,906 B2
- Method for gene transfer into gamma-delta type T cell26 May 2026US 12,637,658 B2Mie University
- RNA-guided nucleic acid modifying enzymes and methods of use thereof26 May 2026US 12,637,691 B2The Regents of the University of California
- T cell receptors and methods of use thereof12 May 2026US 12,624,082 B2University Health Network
- Digital droplet based assay for detecting replication competent lentiviral vector1 Oct 2026US 2026/0297693 A1Sana Biotechnology, Inc.
- Dual targeted gene therapy17 Sep 2026US 2026/0275377 A1Kelonia Therapeutics, Inc.
- Hla-a3-restricted t cell receptors against braf with v600e mutation20 Aug 2026US 2026/0242513 A1The United States of America, as represented by the Secretary, Department of Health and Human Servic
- Modified gamma delta t cells20 Aug 2026US 2026/0242730 A1Pointloma Biosciences, Inc.
- T cell receptors targeting tp53 hotspot mutations and uses thereof13 Aug 2026US 2026/0232801 A1Memorial Hospital for Cancer and Allied Diseases
Most cited
By later US patents
- In vivo introduction and expression of foreign genetic material in epithelial cells586US 4,980,286 AWhitehead Institute for Biomedical Research · 1990
- Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system353US 5,082,670 AThe Regents of the University of California · 1992
- Vector and method of use for nucleic acid delivery to non-dividing cells323US 6,013,516 AThe Salk Institute for Biological Studies · 2000
- Introduction and expression of foreign genetic material in epithelial cells279US 4,868,116 AWhitehead Institute for Biomedical Research · 1989
- Retroviral gene transfer into diploid fibroblasts for gene therapy274US 5,219,740 AFred Hutchinson Cancer Research Center · 1993